Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model

Basic and Clinical Pharmacology and Toxicology

Volumn 97, Issue 4, 2005, Pages 222-229

  Yu, Zhiqian ^a   Funayama, Hiromi ^a   Deng, Xue ^a   Kuroishi, Toshinobu ^a   Sasano, Takashi ^a   Sugawara, Shunji ^a   Endo, Yasuo ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b Graduate School of Dentistry   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DEXAMETHASONE; INTERLEUKIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; EXPERIMENTAL MODEL; INFLAMMATION; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PLEURA FLUID; PRIORITY JOURNAL; SPLENOMEGALY;

ALENDRONATE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPIRIN; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DEXAMETHASONE; HISTIDINE DECARBOXYLASE; INFLAMMATION; INTERLEUKIN-1; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; ORGAN SIZE; SCLEROSIS; SPLEEN; TIBIA;

MURINAE;

EID: 26444611791     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto_138.x     Document Type: Article

References (51)

1. Adami, S., A. K. Bhalla, R. Dorizzi, F. Montesani, S. Rosini, G. Salvagno & V. Lo Cascio: The acute phase response after bisphosphonate administration. Calcif. Tissue Int. 1987, 41, 326-331.
2. Ayada, K., S. Oguri, K. Yamaguchi, K. Kumagai & Y. Endo: Elevation of histidine decarboxylase activity in the stomach of mice by ulcerogenic drugs. Eur. J. Pharmacol. 2003, 460, 63-69.
3. Blank, M. A., B. L. Ems, G. W. Gibson, W. R. Myers, S. K. Berman, R. J. Phipps & P. N. Smith: Nonclinical model for assessing gastric effects of bisphosphonates. Dig. Dis. Sci. 1997, 42, 281-288.
4. Blank, M. A., G. W. Gibson, W. R. Myers, T. A. Dierckman, R. J. Phipps & P. N. Smith: Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Alim. Pharmacol. Ther. 2000, 14, 1215-1223.
5. Bonjour, J. P., R. Rizzoli, P. Ammann & T. Chevalley: Bisphosphonates in clinical medicine. In: Bone and mineral research, vol. 8. Eds.: N. M. Heershe & J. K. Kanis. Elsevier Science BV, Amsterdam, Holland, 1994, pp. 205-264.
6. Devogelaer, J. P., J. Malghem, B. Maldague & J. Nagant de Deuxchaisnes: Radiological manifestation of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987, 16, 360-363.
7. Dewhirst, F. E., P. Stashenko, J. E. Mole & T. Tsurumachi: Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1β. J. Immunol. 1985, 135, 2562-2568.
8. Dinarello, C. A.: Biologic basis for interleukin-1 in disease. Blood 1996, 87, 2095-2147.
9. Endo, Y., N. Nakamura, T. Kikuchi, H. Shinoda, K. Takeda, Y. Nitta & K. Kumagai: Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif. Tissue Int. 1993, 52, 248-254.
10. Endo, Y., M. Shibazaki, M. Nakamura & H. Kosugi: Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Brit. J. Pharmacol. 1999, 126, 903-910.
11. Fleisch, H. A.: Bisphosphonates: preclinical aspects and use in osteoporosis. Anal. Med. 1997, 29, 56-62.
12. Forman, B. M., B. Ruan, J. Chen, G. J. Schroepfer Jr. & R. M. Evans: The orphan nuclear receptor LXRa is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. USA 1997, 94, 10588-10593.
13. Frith, J. C. & M. D. Rogers: Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J. Bone Miner. Res. 2003, 18, 204-212.
14. Funayama, H., H. Mayanagi, H. Takada & Y. Endo: Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate. Arch. Oral Biol. 2000, 45, 787-795.
15. Funayama, H., M. Ohsako, Y. Monma, H. Mayanagi, S. Sugawara & Y. Endo: Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate. Calcif. Tissue Int. 2005, in press.
16. Geddes, A. D., S. M. D'Souza, F. H. Ebentino & J. I. Kenneth: Bisphosphonates: structure-activity relationships and therapeutic implications. In: Bone and mineral research, vol 8. Eds.: N. M. Heershe & J. K. Kanis. Elsevier Science BV, Amsterdam, Holland, 1994, pp 265-306.
17. Glorieux, F. H., N. J. Bishop, H. Plotkin, G. Chabot, G. Lanoue & R. Travers: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New Engl. J. Med. 1998, 339, 947-952.
18. Harinck, H. I. J., S. E. Papapoulos, H. J. Blanksma, A. J. Moolenaar, P. Vermeij & O. L. M. Bijvoet: Paget's disease of bone: early and late responses to three modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Brit. Med. J. 1987, 295, 1301-1305.
19. Horai, R., M. Aasano, K. Sudo, H. Kanuka, M. Suzuki, M. Nishihara, M. Takahashi & Y. Iwakura: Production of mice deficient in genes for interleukin(IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonists shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 1998, 187, 1463-1475.
20. Katagiri, T. & N. Takahashi: Regulatory mechanisms of osteoblast and osteoclasts differentiation. Oral. Dis. 2002, 8, 147-159.
21. Kimble, R. B., J. L. Vannice, D. C., R. C. Bloedow Thomson, W. Hopfer, V. T. Kung, C. Brownfield & R. Pacifici: Interleukin-1receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. 1994, 93, 1959-1967.
22. Kunzmann, V., E. Bauer & M. Wilhelm: γδ T-cell stimulation by pamidronate. New Engl. J. Med. 1999, 340, 737-738.
23. Kunzmann, V., E. Bauer, J. Feurle, F Weißinger, H.-P. Tony & M. Wilhelm: Stimulation of γδ cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96, 384-392.
24. Macarol, V. & F. T. Frauenfelder: Pamidronate disodium and possible ocular adverse drug reactions. Amer. J. Ophthamol. 1994, 118, 220-224.
25. Miyagawa, F., Y. Tanaka, S. Yamashita & N. Minato: Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ cells by aminobisphosphonate antigen. J. Immunol. 2001, 166, 5508-5514.
26. Monma, Y., H. Funayama, H. Mayanagi & Y. Endo: Effects of weekly administrations of alendronate+clodronate on young mouse tibia: localized action at the proximal growth plate. Calcif. Tissue Int. 2004, 74, 115-121.
27. Munns, C. F., F. Rauch, R. J. Mier & F. H. Glorieux: Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004, 35, 231-234.
28. Mönkkönen, J., H.-M. Koponen & P. Ylitalo: Comparison of the distribution of three bisphosphonates in mice. Pharmacology & Toxicology 1989, 65, 294-298.
29. Nakamura, M., H. Yagi, Y. Endo, H. Kosugi, T. Ishii & T. Itoh: A time kinetic study of the effect of aminobisphosphonate on murine haemopoiesis. Brit. J. Haematol. 1999, 107, 779-790.
30. Ness, G. C. & C. M. Chambers: Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc. Soc. Exp. Biol. Med. 2000, 224, 8-19.
31. Rauch, F. & F. H. Glorieux: Osteogenesis imperfecta. Lancet 2004, 363, 1377-1385.
32. Rehman, Q. & N. E. Lane: Effect of glucocorticoids on bone density. Med. Pediatr. Oncol. 2003, 41, 212-216.
33. Reid, I. R., A. R. King, C. J. Alexander & H. K. Ibbertson: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)- 1.1-bisphosphonate (APD). Lancet 1988, 1, 143-146.
34. Robinson, R. E., M. C. Nahata, J. R. Hayes, D. L. Batisky, C. M. Bates, & J. D. Mahan: Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 2004, 24, 195-197.
35. Rodan, G. A. & H. A. Fleisch: Bisphosphonates: mechanism of action. J. Clin. Invest. 1996, 97, 2692-2696.
36. Rogers, M. J., S. Gordon, H. L. Benford, F. P. Coxon, S. P. Luckman, J. Mönkkönen & J. C. Frith: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88, 2961-2978.
37. Ruggiero, S. L., B. Mebrotra, T. J. Rosenberg & S. L. Engroff: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 2004, 62, 527-534.
38. Sauty, A., M. Pecherstorfer, I. Zimmer-Roth, P. Fioroni, L. Juillerat, M. Markert, H. Ludwig, P. Leuenberger, P. Burckhardt & D. Thiébaud: Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996, 18, 133-139.
39. Schneider, E., M. Rolli-Derkinderen, M. Arock & M. Dy: Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. 2002, 23, 255-263.
40. Schweitzer, D. H., M. O. V. D. Ruit, G. V. D. Pruijm, C. W. G. M. Löwik & S. E. Papapoulos: Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J. Bone Mineral Res. 1995, 10, 956-962.
41. Siris, E.: Bisphosphonates and iritis. Lancet 1993, 341, 436-437.
42. Sugawara, S., M. Shibazaki, H. Takada, K. Kosugi & Y. Endo: Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice. Brit. J. Pharmacol. 1998, 125, 735-740.
43. Thiébaud, D., A. Sauty, P. Burckhardt, P. Leuenberger, L. Sitzler, J. R. Green, A. Kandra, J. Zieschange & P. Ibarra de Palacios: An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif. Tissue Int. 1997, 61, 386-392.
44. Thompson, K. & M. J. Rogers: Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro. J. Bone Mineral Res. 2004, 19, 278-288.
45. Töyräs, A., J. Ollikainen, M. Taskinen & J. Mönkkönen: Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur. J. Pharmaceutical Sci. 2003, 19, 223-230.
46. Vane, J. R. & R. M. Botting: The mechanism of action of aspirin. Thromb. Res. 2003, 110, 255-258.
47. Watanabe, M., T. Tabata, J. I. Huh, T. Inai, A. Tsuboi, K. Sasaki & Y. Endo: Possible involvement of histamine in muscular fatigue in temporomandibular disorders: animal and human subjects. J. Dent. Res. 1999, 78, 769-775.
48. Weinstein, R. S., J.-R. Chen, C. C. Powers, S. A. Stewart, R. D. Randes, T. Bellido, R. L. Jilka, A. M. Parfitt & S. C. Manolagas: Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 2002, 109, 1041-1048.
49. Yamaguchi, K., K. Motegi, Y. Iwakura & Y. Endo: Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Brit. J. Pharmacol. 2000, 130, 1646-1654.
50. Yin, M.-J., Y. Yamamoto & R. B. Gaynor: The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998, 396, 77-80.
51. Yu, Z., Y. Ohtaki, K. Kai, T. Sasano, H. Shimauchi, T. Yokochi, H. Takada, S. Sugawara, K. Kumagai & Y. Endo: Critical roles of platelets in lipopolysaccharide-induced lethality: effects of glycyrrhizin and possible strategy for acute respiratory distress syndrome. Int. Immunopharmacol. 2005, 5, 571-580.